In This Story LLY +0.26% BIIB -0.96% The European Union’s health regulator on Friday rejected Eli Lilly’s ( LLY +0.26% ) Alzheimer’s drug, Kisunla, citing risks of brain swelling and bleeding . It’s a major setback for the company as it competes with a similar treatment from Biogen ( BIIB -0.96% ) and Eisai. Suggested Reading Starbucks sets new speed goals after reports of 30 to 40-minute waits See inside Jennifer Lopez’s new $17.5 million home New fund aims to protect portfolios from